

References

1. Roger VL. Epidemiology of myocardial infarction. *Med Clin North American*. 2007 Jul; 91(4): 537–ix. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2537993/>. Accessed April 11, 2019.
2. Sweis R. Overview of Coronary Artery Disease. Merck Manual. <https://www.merckmanuals.com/professional/cardiovascular-disorders/coronary-artery-disease/overview-of-coronary-artery-disease>. Published December 2018. Accessed April 10, 2019.
3. Ischemic Heart Disease. National Heart, Lung, and Blood Institute. <https://www.nhlbi.nih.gov/health-topics/ischemic-heart-disease>. Published February 2019. Accessed April 10, 2019.
4. Teo K. Peripheral Arterial Disease. Merck Manual. <https://www.merckmanuals.com/professional/cardiovascular-disorders/peripheral-arterial-disorders/peripheral-arterial-disease>. Published December 2017. Accessed April 10, 2019.
5. Dauerman, HL. Reconsidering the Necessity of Aspirin in Stable Coronary Artery Disease. *Journal of the American College of Cardiology*. 2014;64:1437-1440. <http://www.onlinejacc.org/content/64/14/1437>. Accessed April 11, 2019.
6. Bavry, AA. Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. *The American Journal of Medicine*. 2015;128:137-143. [https://www.amjmed.com/article/S0002-9343\(14\)00907-3/pdf](https://www.amjmed.com/article/S0002-9343(14)00907-3/pdf). Accessed April 11, 2019.
7. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009;373:1849-1860. [https://www.amjmed.com/article/S0002-9343\(14\)00907-3/pdf](https://www.amjmed.com/article/S0002-9343(14)00907-3/pdf). Accessed April 11, 2019.
8. Sanmuganathan, PS. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. *Heart*. 2001;85:265-271. <https://heart.bmj.com/content/85/3/265>. Accessed April 11, 2019.
9. Poredos, P. Low-dose aspirin for PAD patients. *European Society of Cardiology*. 2009;8:6-14. <https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-8/Low-dose-aspirin-for-PAD-patients>. Accessed April 11, 2019.
10. Highlight of Prescribing Information (Xarelto). U.S. Food & Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202439s025lbl.pdf. Published October 2018. Accessed April 11, 2019.
11. Haas, S. Factor Xa Inhibitors. Thrombosis Adviser. <https://www.thrombosisadviser.com/factor-xa-inhibitors/>. Published February 2019. Accessed April 11, 2019.
12. Korjian S, Braunwald E, Daaboul Y, et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights

from the ATLAS ACS 2-TIMI 51 trial. *European Heart Journal: Acute Cardiovascular Care*. 2017;161:186-193. <https://www.ncbi.nlm.nih.gov/pubmed/29249166>. Accessed April 11, 2019.

13. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med*. 2017;377:1319-30. doi: 10.1056/NEJMoa1709118.
14. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. *N Engl J Med*. 2018; 378:2191-2201. doi: 10.1056/NEJMoa1802686.
15. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. *N Engl J Med*. 2017;376:1211-22. doi: 10.1056/NEJMoa1700518.
16. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;391:219–229. doi: 10.1016/S0140-6736(17)32409-1.
17. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2017. doi: 10.1016/S0140-6736(17)32458-3.
18. Gibson CM, Levitan B, Gibsop WJ, et al. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. *Journal of the American College of Cardiology*. 2018; 72;2:129-136. doi: 10.1016/j.jacc.2018.04.055.
19. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. *N Engl J Med*. 2012; 366:9-19. doi: 10.1056/NEJMoa1112277.
20. Stewart, J. Xarelto Approval History. Drugs.com. <https://www.drugs.com/history/xarelto.html>. Published October 15, 2019. Accessed March 5, 2020.